Literature DB >> 23698372

Cancer: Drug for an 'undruggable' protein.

Nicole M Baker, Channing J Der.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23698372      PMCID： PMC4902159          DOI： 10.1038/nature12248

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  The delta subunit of retinal rod cGMP phosphodiesterase regulates the membrane association of Ras and Rap GTPases.

Authors:  Vanessa Nancy; Isabelle Callebaut; Ahmed El Marjou; Jean de Gunzburg
Journal:  J Biol Chem       Date:  2002-01-10       Impact factor: 5.157

2.  The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins.

Authors:  Anchal Chandra; Hernán E Grecco; Venkat Pisupati; David Perera; Liam Cassidy; Ferdinandos Skoulidis; Shehab A Ismail; Christian Hedberg; Michael Hanzal-Bayer; Ashok R Venkitaraman; Alfred Wittinghofer; Philippe I H Bastiaens
Journal:  Nat Cell Biol       Date:  2011-12-18       Impact factor: 28.824

3.  Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo.

Authors:  Shehab A Ismail; Yong-Xiang Chen; Alexandra Rusinova; Anchal Chandra; Martin Bierbaum; Lothar Gremer; Gemma Triola; Herbert Waldmann; Philippe I H Bastiaens; Alfred Wittinghofer
Journal:  Nat Chem Biol       Date:  2011-10-16       Impact factor: 15.040

4.  Ras history: The saga continues.

Authors:  Adrienne D Cox; Channing J Der
Journal:  Small GTPases       Date:  2010-07

Review 5.  Regulating the regulator: post-translational modification of RAS.

Authors:  Ian M Ahearn; Kevin Haigis; Dafna Bar-Sagi; Mark R Philips
Journal:  Nat Rev Mol Cell Biol       Date:  2011-12-22       Impact factor: 94.444

6.  Ras hitchhikes on PDE6δ.

Authors:  Mark R Philips
Journal:  Nat Cell Biol       Date:  2012-02-02       Impact factor: 28.824

7.  Targeting protein prenylation for cancer therapy.

Authors:  Norbert Berndt; Andrew D Hamilton; Saïd M Sebti
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

8.  Deletion of PrBP/delta impedes transport of GRK1 and PDE6 catalytic subunits to photoreceptor outer segments.

Authors:  H Zhang; S Li; T Doan; F Rieke; P B Detwiler; J M Frederick; W Baehr
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-11       Impact factor: 11.205

9.  Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.

Authors:  Gunther Zimmermann; Björn Papke; Shehab Ismail; Nachiket Vartak; Anchal Chandra; Maike Hoffmann; Stephan A Hahn; Gemma Triola; Alfred Wittinghofer; Philippe I H Bastiaens; Herbert Waldmann
Journal:  Nature       Date:  2013-05-22       Impact factor: 49.962

10.  Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.

Authors:  Daniel Laheru; Preeti Shah; N V Rajeshkumar; Florencia McAllister; Gretchen Taylor; Howard Goldsweig; Dung T Le; Ross Donehower; Antonio Jimeno; Sheila Linden; Ming Zhao; Dongweon Song; Michelle A Rudek; Manuel Hidalgo
Journal:  Invest New Drugs       Date:  2012-05-01       Impact factor: 3.850
  10 in total
  26 in total

Review 1.  The influence of subclonal resistance mutations on targeted cancer therapy.

Authors:  Michael W Schmitt; Lawrence A Loeb; Jesse J Salk
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 2.  Covalent Inhibition in Drug Discovery.

Authors:  Avick Kumar Ghosh; Indranil Samanta; Anushree Mondal; Wenshe Ray Liu
Journal:  ChemMedChem       Date:  2019-03-26       Impact factor: 3.466

3.  Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.

Authors:  Amro Aboukameel; Irfana Muqbil; William Senapedis; Erkan Baloglu; Yosef Landesman; Sharon Shacham; Michael Kauffman; Philip A Philip; Ramzi M Mohammad; Asfar S Azmi
Journal:  Mol Cancer Ther       Date:  2016-11-15       Impact factor: 6.261

Review 4.  Oncogenic protein interfaces: small molecules, big challenges.

Authors:  Tracy L Nero; Craig J Morton; Jessica K Holien; Jerome Wielens; Michael W Parker
Journal:  Nat Rev Cancer       Date:  2014-03-13       Impact factor: 60.716

5.  Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.

Authors:  Piergiorgio Pettazzoni; Andrea Viale; Parantu Shah; Alessandro Carugo; Haoqiang Ying; Huamin Wang; Giannicola Genovese; Sahil Seth; Rosalba Minelli; Tessa Green; Emmet Huang-Hobbs; Denise Corti; Nora Sanchez; Luigi Nezi; Matteo Marchesini; Avnish Kapoor; Wantong Yao; Maria E Di Francesco; Alessia Petrocchi; Angela K Deem; Kenneth Scott; Simona Colla; Gordon B Mills; Jason B Fleming; Timothy P Heffernan; Philip Jones; Carlo Toniatti; Ronald A DePinho; Giulio F Draetta
Journal:  Cancer Res       Date:  2015-03-03       Impact factor: 12.701

Review 6.  Approaches of targeting Rho GTPases in cancer drug discovery.

Authors:  Yuan Lin; Yi Zheng
Journal:  Expert Opin Drug Discov       Date:  2015-06-18       Impact factor: 6.098

Review 7.  Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.

Authors:  Jun Zhang; Dongkyoo Park; Dong M Shin; Xingming Deng
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-11-17       Impact factor: 3.848

Review 8.  Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.

Authors:  R Mandal; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

9.  Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.

Authors:  Sergey I Nikolaev; Marco Garieri; Federico Santoni; Emilie Falconnet; Pascale Ribaux; Michel Guipponi; Aoife Murray; Jürgen Groet; Emanuela Giarin; Giuseppe Basso; Dean Nizetic; Stylianos E Antonarakis
Journal:  Nat Commun       Date:  2014-08-08       Impact factor: 14.919

Review 10.  CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries.

Authors:  K Sreedurgalakshmi; R Srikar; Reena Rajkumari
Journal:  Cancer Gene Ther       Date:  2020-11-15       Impact factor: 5.987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.